Five licensed dispensaries will open in Iowa in the near future, and Wednesday brought a preview of the products that will be displayed in each location, available for those who utilize marijuana for medical treatment and pain management.

MedPharm Iowa is the only licensed medical marijuana manufacturer for the state. They make tinctures, capsules, and creams for around 1,000 customers already.

The company unveiled new products with a range of cannabidiol, or CBD, levels. The products also have a varying range of tetrahydrocannibidiol, or THC, in the products. CBD offers pain management help and also improves control of seizures and symptoms of Parkinson’s Disease, all without the intoxication impact. THC, which has a psychoactive impact, helps those with cancer, terminal illness and multiple sclerosis, among other illnesses, to manage pain.

The products will be offered in ratios of CBD to THC; namely, 20:1, 2:1, 1:1 and 1:20. Each ratio corresponds to specific illnesses and provides the necessary degree of pain management or symptom control each illness requires. Examples include Crohn’s Disease and seizures – 20:1; Cancer, ALS, AIDS/HIV – 1:1 and terminal illness and untreatable pain – 1:20.

The store layout for each dispensary location was created with the patient in mind. The design has been compared to the familiar comfort of a widely available cell phone provider, allowing visitors to view products and enter a very open and familiar seeming layout during a first visit to the licensed dispensaries.

Prices are a concern for potential users as well. So far, the new products will come with the following price ranges: creams will be available in the $65 to $85 price range, pills can be obtained at a trial price of $10 to $25 or within the range of $30 to $130 and tinctures can be purchased for anywhere from $50 to $130. Creams are only available in a 2:1 ratio, while pills will be available in the 20:1, 1:1 and 1:20 rations and tinctures are being produced in the 20:1, 1:1 and 1:20 ratios.

The dispensaries are slated to open in Council Bluffs, Sioux City, Windsor Heights, Davenport, and Waterloo. The success of these locations will be closely monitored, as there are concerns about whether or not the state’s market can sustain MedPharm Iowa and other potential vendors.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.